Bevacizumab‐enhanced antitumor effect of 5‐fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2‐specificity protein 1 pathway

Bevacizumab (Bv) can be used synergistically with fluoropyrimidine‐based chemotherapy to treat colorectal cancer. Whether and how it affects the delivery of fluoropyrimidine drugs is unknown. The present study aimed to explore the effect of Bv on the delivery of 5‐fluorouracil (5‐FU) to tumors and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenyue, Zhang, Jingwei, Yao, Xuequan, Jiang, Chao, Ni, Ping, Cheng, Lingge, Liu, Jiali, Ni, Suiying, Chen, Qianying, Li, Qingran, Zhou, Kai, Wang, Guangji, Zhou, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172063/
https://www.ncbi.nlm.nih.gov/pubmed/30151975
http://dx.doi.org/10.1111/cas.13779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172063/
https://www.ncbi.nlm.nih.gov/pubmed/30151975
http://dx.doi.org/10.1111/cas.13779

Ejemplares similares